PT  - JOURNAL ARTICLE
AU  - Guan, Wei-jie
AU  - Liang, Wen-hua
AU  - Zhao, Yi
AU  - Liang, Heng-rui
AU  - Chen, Zi-sheng
AU  - Li, Yi-min
AU  - Liu, Xiao-qing
AU  - Chen, Ru-chong
AU  - Tang, Chun-li
AU  - Wang, Tao
AU  - Ou, Chun-quan
AU  - Li, Li
AU  - Chen, Ping-yan
AU  - Sang, Ling
AU  - Wang, Wei
AU  - Li, Jian-fu
AU  - Li, Cai-chen
AU  - Ou, Li-min
AU  - Cheng, Bo
AU  - Xiong, Shan
AU  - Ni, Zheng-yi
AU  - Xiang, Jie
AU  - Hu, Yu
AU  - Liu, Lei
AU  - Shan, Hong
AU  - Lei, Chun-liang
AU  - Peng, Yi-xiang
AU  - Wei, Li
AU  - Liu, Yong
AU  - Hu, Ya-hua
AU  - Peng, Peng
AU  - Wang, Jian-ming
AU  - Liu, Ji-yang
AU  - Chen, Zhong
AU  - Li, Gang
AU  - Zheng, Zhi-jian
AU  - Qiu, Shao-qin
AU  - Luo, Jie
AU  - Ye, Chang-jiang
AU  - Zhu, Shao-yong
AU  - Cheng, Lin-ling
AU  - Ye, Feng
AU  - Li, Shi-yue
AU  - Zheng, Jin-ping
AU  - Zhang, Nuo-fu
AU  - Zhong, Nan-shan
AU  - He, Jian-xing
ED - 
TI  - Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis
AID  - 10.1183/13993003.00547-2020
DP  - 2020 May 01
TA  - European Respiratory Journal
PG  - 2000547
VI  - 55
IP  - 5
4099  - https://publications.ersnet.org//content/55/5/2000547.short
4100  - https://publications.ersnet.org//content/55/5/2000547.full
SO  - Eur Respir J2020 May 01; 55
AB  - Background The coronavirus disease 2019 (COVID-19) outbreak is evolving rapidly worldwide.Objective To evaluate the risk of serious adverse outcomes in patients with COVID-19 by stratifying the comorbidity status.Methods We analysed data from 1590 laboratory confirmed hospitalised patients from 575 hospitals in 31 provinces/autonomous regions/provincial municipalities across mainland China between 11 December 2019 and 31 January 2020. We analysed the composite end-points, which consisted of admission to an intensive care unit, invasive ventilation or death. The risk of reaching the composite end-points was compared according to the presence and number of comorbidities.Results The mean age was 48.9 years and 686 (42.7%) patients were female. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached the composite end-points. 399 (25.1%) reported having at least one comorbidity. The most prevalent comorbidity was hypertension (16.9%), followed by diabetes (8.2%). 130 (8.2%) patients reported having two or more comorbidities. After adjusting for age and smoking status, COPD (HR (95% CI) 2.681 (1.424–5.048)), diabetes (1.59 (1.03–2.45)), hypertension (1.58 (1.07–2.32)) and malignancy (3.50 (1.60–7.64)) were risk factors of reaching the composite end-points. The hazard ratio (95% CI) was 1.79 (1.16–2.77) among patients with at least one comorbidity and 2.59 (1.61–4.17) among patients with two or more comorbidities.Conclusion Among laboratory confirmed cases of COVID-19, patients with any comorbidity yielded poorer clinical outcomes than those without. A greater number of comorbidities also correlated with poorer clinical outcomes.The presence and number of comorbidities predict clinical outcomes of COVID-19 http://bit.ly/3b9ibw5